

Urvi M Parikh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4318513/publications.pdf>

Version: 2024-02-01

32
papers

2,672
citations

516710

16
h-index

434195

31
g-index

32
all docs

32
docs citations

32
times ranked

3193
citing authors

#	ARTICLE	IF	CITATIONS
1	Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. <i>New England Journal of Medicine</i> , 2015, 372, 509-518.	27.0	1,094
2	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2121-2132.	27.0	624
3	The K65R Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Exhibits Bidirectional Phenotypic Antagonism with Thymidine Analog Mutations. <i>Journal of Virology</i> , 2006, 80, 4971-4977.	3.4	117
4	Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e815-e821.	5.8	113
5	Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV</i> , 2021, 8, e87-e95.	4.7	70
6	Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. <i>Aids</i> , 2007, 21, 1405-1414.	2.2	68
7	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). <i>Clinical Infectious Diseases</i> , 2022, 75, e630-e644.	5.8	65
8	Antagonism between the HIV-1 Reverse Transcriptase Mutation K65R and Thymidine Analogue Mutations at the Genomic Level. <i>Journal of Infectious Diseases</i> , 2006, 194, 651-660.	4.0	64
9	In Vitro Activity of Structurally Diverse Nucleoside Analogs against Human Immunodeficiency Virus Type 1 with the K65R Mutation in Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1139-1144.	3.2	60
10	Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 49-55.	3.8	54
11	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naïve Adults in South Africa, 2000-2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , 2019, 9, 26-34.	7.1	51
12	Future technologies for monitoring HIV drug resistance and cure. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 182-189.	3.8	45
13	Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA). <i>Journal of Infectious Diseases</i> , 2016, 213, 1013-1017.	4.0	40
14	Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009). <i>PLoS ONE</i> , 2013, 8, e59787.	2.5	27
15	The fourth generation Alere TM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples. <i>Journal of Clinical Virology</i> , 2017, 94, 15-21.	3.1	25
16	Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. <i>Clinical Infectious Diseases</i> , 2016, 63, 539-547.	5.8	24
17	Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2022, 9, e353-e362.	4.7	19
18	Loss of Innate Host Defense Following Unprotected Vaginal Sex. <i>Journal of Infectious Diseases</i> , 2016, 213, 840-847.	4.0	17

#	ARTICLE	IF	CITATIONS
19	Dapivirine vaginal ring for <sc>HIV</sc> prevention: modelling health outcomes, drug resistance and cost-effectiveness. <i>Journal of the International AIDS Society</i> , 2019, 22, e25282.	3.0	16
20	Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception. <i>AIDS and Behavior</i> , 2017, 21, 2173-2179.	2.7	14
21	Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	12
22	Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw125.	0.9	9
23	Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring. <i>Clinical Infectious Diseases</i> , 2019, 69, 523-529.	5.8	8
24	How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 213-221.	3.8	8
25	HIV drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25833.	3.0	7
26	Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa. <i>Antiviral Chemistry and Chemotherapy</i> , 2018, 26, 204020661876298.	0.6	6
27	A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 794-804.	1.1	5
28	Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens. <i>Future Microbiology</i> , 2012, 7, 929-932.	2.0	4
29	High Prevalence of Cross-resistance to Rilpivirine in Subtype C HIV-1 Isolates from First-line ART Failures in South Africa. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A166-A166.	1.1	3
30	Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa. <i>AIDS and Behavior</i> , 2015, 19, 2076-2086.	2.7	2
31	Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	1
32	Casting a Wide Net: HIV Drug Resistance Monitoring in Pre-Exposure Prophylaxis Seroconverters in the Global Evaluation of Microbicide Sensitivity Project. <i>Global Health, Science and Practice</i> , 2022, 10, .	1.7	0